Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms by Andrea Corsello (5172026)

“…</p><p>Results</p><p>Patients with ileal or pancreatic NENs showed increased plasma levels of total-CgA and CgA_1-76 fragment (vasostatin-1, VS-1) compared to controls [median (25^th-75^th-percentiles); total-CgA: 1.85 nM (1.01–4.28) <i>vs</i> 0.75 nM (0.52–0.89), <i>p</i> = 0.004; VS-1: 2.76 nM (1.09–7.10) <i>vs</i> 0.29 nM (0.26–0.32), <i>p</i><0.001, respectively], but not of CgA_1-439 or CgA_1-373 fragment. …”

Analysis of change in mature INPs, GMCs and neurons in the type II NB lineage on depletion of mitochondrial morphology proteins. by Dnyanesh Dubal (12085942)

Decreased social behaviors in SCR (+/−) mice. by Ikuko Yao (229082)

Ki-67 immunohistochemistry of corneal tissues. by Vindhya Koppaka (845151)

Photosynthesis decreases in N stressed cells. by Steve Dagenais Bellefeuille (654383)

Drp1^SD overexpression partially alleviates the differentiation defect seen in <i>notch</i> RNAi expressing type II NB lineages. by Dnyanesh Dubal (12085942)

BMT decreased weight of different organs. by Saeed Katiraei (3956147)

BMT decreased diet-induced obesity. by Saeed Katiraei (3956147)

Nanoparticle formulation decreases curcumin cytotoxicity. by Upendhar Gandapu (208623)

p53 expression in mouse corneas. by Vindhya Koppaka (845151)

Behavior of split^<50cM <i>ClvR</i> V2 with linkage. by Georg Oberhofer (3401438)

“…<p>Incorporating linkage into split <i>ClvR</i> (split^<50cM <i>ClvR</i> V2) results in a graded increase in drive strength, and duration of <i>Rescue</i>/Cargo/gRNAs at high frequency, as the degree of linkage increases (map distance decreases). …”

Metformin lotion decreases TGF-β1 levels in the wounded skin of rats after 10 days of wound healing. by Jianying Zhang (256508)

Behavior of split^<50cM <i>ClvR</i> V1 with linkage. by Georg Oberhofer (3401438)

BrDU labeling of corneal epithelial cells. by Vindhya Koppaka (845151)

Difference in changes in ODI and EQ-5D-5L scores among three groups (n = 45). by Jae-Hong Kim (124622)

Subjects:

Changes in outcome measures after treatment completion in the three groups. by Jae-Hong Kim (124622)

Subjects:

Homogeneity tests for baseline demographic characteristics and study variables for 45 patients with chronic non-specific low back pain. by Jae-Hong Kim (124622)

Subjects:

Changes in vital signs (Week4 vs. Week0) after treatment completion within the three groups. by Jae-Hong Kim (124622)

Subjects:

CONSORT 2010 flow diagram. by Jae-Hong Kim (124622)

Subjects:

Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) statement. by Jae-Hong Kim (124622)

Subjects: